お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
市場調査レポート
商品コード
918178

進行腎細胞がん - 市場洞察、疫学、予測

Advanced Renal Cell Carcinoma (RCC) Market Insight, Epidemiology and Market Forecast - 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 150 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.13円
進行腎細胞がん - 市場洞察、疫学、予測
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 150 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、主要8カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本、中国)の進行腎細胞がん市場について調査し、疾病の概要や現行の治療法、上市済み治療薬および新薬のプロファイル、主要8カ国の市場動向、疫学的予測、セグメント別の罹患数の推移と予測、アンメットニーズ、市場の成長要因および障壁などを包括的にまとめています。

目次

第1章 重要洞察

第2章 進行腎細胞がん市場の概要

  • 進行腎細胞がんの分布(実数値)
  • 進行腎細胞がんの分布(予測値)

第3章 疾病背景と概要:進行腎細胞がん

  • イントロダクション
  • 組織学的サブタイプおよび関連分子経路
    • 明細胞腎細胞がん
    • 非明細胞腎細胞がん
  • 腎細胞がんの病理
  • 病態生理
  • 進行腎細胞がんの危険因子
  • 腎細胞がんのメカニズム
  • 腎細胞がんの病期分類
  • 腎細胞がんの遺伝病理学
  • 腎細胞がんのエピジェネティクス
  • 腫瘍の挙動と予後の分子マーカー
  • 腎細胞がんの代謝経路と標的
  • 腎細胞がんにおける免疫系の役割
  • バイオマーカー
    • 分子バイオマーカー
    • 炎症性タンパク質
    • 尿中分子マーカー
  • 診断
  • 診断ガイドライン
    • 腎細胞がんに関する欧州泌尿器科ガイドライン:2019
    • 腎腫瘤および限局性腎がん:AUAガイドライン(2017)
    • 腎細胞がん:診断のためのESMO臨床診療ガイドライン
  • 要約:進行腎細胞がん

第4章 承認された機関

  • 米国
  • 欧州
  • 日本

第5章 疫学と患者人口

  • 主な調査結果
  • 主要8カ国の進行腎細胞がんの総有病数

第6章 国別の疫学予測

  • 米国
    • 仮定と理論的根拠
    • 腎細胞がんの診断罹患数
    • 腎細胞がんの診断罹患数:性別
    • 腎細胞がんの診断罹患数:病型別
    • 腎細胞がんの診断罹患数:病期別
    • 進行/転移性腎細胞がんの症例数
  • EU5カ国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第7章 治療

  • 外科的管理
    • 腎部分切除術(PN)
    • 根治的腎摘除術
    • 細胞減少性腎摘除術
    • 非外科的腫瘍治療
  • 全身療法
    • 免疫療法
    • PD-L1療法
  • 標的療法
    • サイトカイン療法
    • ソラフェニブ
    • スニチニブ
    • ベバシズマブ
    • パゾパニブ
    • アキシチニブ
    • カボザンチニブ
    • テムシロリムス
    • ロカプルデンセル-T
    • アベルマブ
  • 放射線療法
    • 定位放射線手術(SRS)
    • 術中RT(IORT)
  • 腎細胞がん:治療・フォローアップに関するESMO臨床診療ガイドライン(2019)
  • 腎細胞がんに関する欧州泌尿器学会(EAU)ガイドライン(2018)
  • NCCNガイドラインの改定:転移性腎がんの管理(2019)
  • 治療アルゴリズム

第8章 アンメットニーズ

第9章 上市済み治療薬

  • Keytruda/Inlyta:Merck/Pfizer
    • 製品概要
    • 製品開発動向
    • 臨床動向
    • 製品プロファイル
  • Opdivo/Yervoy:Bristol-Myers Squibb
  • Bavencio/Inlyta:Merck/Pfizer
  • Lenvima/Afinitor:エーザイ/Novartis
  • Sutent:Pfizer
  • Cabometyx:Exelixis
  • Avastin:Genentech (Roche)
  • Votrient: Novartis
  • Fotivda: AVEO Oncology
  • Nexavar: Bayer HealthCare Pharmaceuticals
  • Torisel: Pfizer

第10章 新薬

  • キークロスコンペティション
  • Bempegaldesleukin (NKTR-214) and NKTR-262:Nektar Therapeutics
    • 製品概要
    • 製品開発動向
    • 臨床動向
    • 製品プロファイル
  • Vorolanib (CM082):Betta Pharmaceuticals/Xcovery Holdings
  • Telaglenastat (CB-839):Calithera Biosciences
  • Savolitinib (AZD-6094):AstraZeneca
  • Nintedanib:Boehringer Ingelheim Pharmaceuticals
  • Camrelizumab (SHR-1210):Jiangsu HengRui Medicine
  • Crizotinib:Pfizer
  • Activated CIK and CD3-MUC1 Bispecific Antibody:Benhealth
  • Biopharmaceutical
  • Mavorixafor (X4P-001):X4 Pharmaceuticals
  • Ibrutinib/Nivolumab:Pharmacyclics/Bristol-Myers Squibb
  • Pembrolizumab (MK-3475)/ Bevacizumab:Merck/Genentech (Roche)

第11章 新規併用療法

  • Nivolumab/Cabozantinib:Bristol-Myers Squibb/Exelixis Current Pipeline Activity
  • Pembrolizumab/Epacadostat:Merck/Incyte Corporation
  • Pembrolizumab/Denosumab:Merck/Amgen
  • Pembrolizumab/Pegylated Interferon Alfa-2b/Ipilimumab:Merck/ Bristol-Myers Squibb
  • Pazopanib + Interferon alpha 2A:Novartis
  • Pembrolizumab/Cabozantinib:Merck/Exelixis
  • Cabozantinib/Sunitinib:Exelixis/Pfizer
  • Nivolumab/Tivozanib:Bristol-Myers Squibb/AVEO Oncology
  • Lenvatinib/Pembrolizumab:エーザイ/Merck

第12章 エキスパートの見解

第13章 主要8カ国の進行腎細胞がん市場の分析

  • 主な調査結果
  • 主要8カ国の市場規模

第14章 米国市場の見通し

  • 米国
    • 総市場規模
    • 市場規模:治療薬別

第15章 EU5カ国市場の見通し

  • ドイツ
    • 総市場規模
    • 市場規模:治療薬別
  • フランス
  • イタリア
  • スペイン
  • 英国

第16章 日本市場の見通し

  • 日本
    • 総市場規模
    • 市場規模:治療薬別

第17章 中国市場の見通し

  • 中国
    • 総市場規模
    • 市場規模:治療薬別

第18章 症例報告

第19章 市場の成長要因

第20章 市場の障壁

第21章 付録

第22章 DelveInsightのサービス内容

第23章 免責事項

第24章 DelveInsightについて

図表

List of Tables

  • Table 1 : 7MM Advanced Renal Cell Carcinoma (RCC) Epidemiology (2017-2030)
  • Table 2 : 7MM Advanced Renal Cell Carcinoma (RCC) Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Advanced Renal Cell Carcinoma (RCC) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Advanced Renal Cell Carcinoma (RCC) Epidemiology in Germany (2017-2030)
  • Table 6 : Advanced Renal Cell Carcinoma (RCC) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Advanced Renal Cell Carcinoma (RCC) Epidemiology in France (2017-2030)
  • Table 8 : Advanced Renal Cell Carcinoma (RCC) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Advanced Renal Cell Carcinoma (RCC) Epidemiology in Italy (2017-2030)
  • Table 10 : Advanced Renal Cell Carcinoma (RCC) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Advanced Renal Cell Carcinoma (RCC) Epidemiology in Spain (2017-2030)
  • Table 12 : Advanced Renal Cell Carcinoma (RCC) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Advanced Renal Cell Carcinoma (RCC) Epidemiology in the UK (2017-2030)
  • Table 14 : Advanced Renal Cell Carcinoma (RCC) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Advanced Renal Cell Carcinoma (RCC) Epidemiology in Japan (2017-2030)
  • Table 16 : Advanced Renal Cell Carcinoma (RCC) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Advanced Renal Cell Carcinoma (RCC) Epidemiology (2017-2030)
  • Figure 2 : 7MM Advanced Renal Cell Carcinoma (RCC) Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Advanced Renal Cell Carcinoma (RCC) Epidemiology in the United States (2017-2030)
  • Figure 4 : Advanced Renal Cell Carcinoma (RCC) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Advanced Renal Cell Carcinoma (RCC) Epidemiology in Germany (2017-2030)
  • Figure 6 : Advanced Renal Cell Carcinoma (RCC) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Advanced Renal Cell Carcinoma (RCC) Epidemiology in France (2017-2030)
  • Figure 8 : Advanced Renal Cell Carcinoma (RCC) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Advanced Renal Cell Carcinoma (RCC) Epidemiology in Italy (2017-2030)
  • Figure 10 : Advanced Renal Cell Carcinoma (RCC) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Advanced Renal Cell Carcinoma (RCC) Epidemiology in Spain (2017-2030)
  • Figure 12 : Advanced Renal Cell Carcinoma (RCC) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Advanced Renal Cell Carcinoma (RCC) Epidemiology in the UK (2017-2030)
  • Figure 14 : Advanced Renal Cell Carcinoma (RCC) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Advanced Renal Cell Carcinoma (RCC) Epidemiology in Japan (2017-2030)
  • Figure 16 : Advanced Renal Cell Carcinoma (RCC) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)
目次
Product Code: DIMI0697

DelveInsight's "Advanced Renal Cell Carcinoma (RCC) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Advanced Renal Cell Carcinoma (RCC), historical and forecasted epidemiology as well as the Advanced Renal Cell Carcinoma (RCC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Advanced Renal Cell Carcinoma (RCC) market report provides current treatment practices, emerging drugs, Advanced Renal Cell Carcinoma (RCC) market share of the individual therapies, current and forecasted Advanced Renal Cell Carcinoma (RCC) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Advanced Renal Cell Carcinoma (RCC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Advanced Renal Cell Carcinoma (RCC) Disease Understanding and Treatment Algorithm

The DelveInsight Advanced Renal Cell Carcinoma (RCC) market report gives a thorough understanding of the Advanced Renal Cell Carcinoma (RCC) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Advanced Renal Cell Carcinoma (RCC).

Treatment

It covers the details of conventional and current medical therapies available in the Advanced Renal Cell Carcinoma (RCC) market for the treatment of the condition. It also provides Advanced Renal Cell Carcinoma (RCC) treatment algorithms and guidelines in the United States, Europe, and Japan.

Advanced Renal Cell Carcinoma (RCC) Epidemiology

The Advanced Renal Cell Carcinoma (RCC) epidemiology division provide insights about historical and current Advanced Renal Cell Carcinoma (RCC) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Advanced Renal Cell Carcinoma (RCC) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Advanced Renal Cell Carcinoma (RCC) Epidemiology

The epidemiology segment also provides the Advanced Renal Cell Carcinoma (RCC) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Advanced Renal Cell Carcinoma (RCC) Drug Chapters

Drug chapter segment of the Advanced Renal Cell Carcinoma (RCC) report encloses the detailed analysis of Advanced Renal Cell Carcinoma (RCC) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Advanced Renal Cell Carcinoma (RCC) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Advanced Renal Cell Carcinoma (RCC) treatment.

Advanced Renal Cell Carcinoma (RCC) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Advanced Renal Cell Carcinoma (RCC) treatment.

Advanced Renal Cell Carcinoma (RCC) Market Outlook

The Advanced Renal Cell Carcinoma (RCC) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Advanced Renal Cell Carcinoma (RCC) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Advanced Renal Cell Carcinoma (RCC) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Advanced Renal Cell Carcinoma (RCC) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Advanced Renal Cell Carcinoma (RCC) market in 7MM.

The United States Market Outlook

This section provides the total Advanced Renal Cell Carcinoma (RCC) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Advanced Renal Cell Carcinoma (RCC) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Advanced Renal Cell Carcinoma (RCC) market size and market size by therapies in Japan is also mentioned.

Advanced Renal Cell Carcinoma (RCC) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Advanced Renal Cell Carcinoma (RCC) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Advanced Renal Cell Carcinoma (RCC) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Advanced Renal Cell Carcinoma (RCC) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Advanced Renal Cell Carcinoma (RCC) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Advanced Renal Cell Carcinoma (RCC) emerging therapies.

Reimbursement Scenario in Advanced Renal Cell Carcinoma (RCC)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Advanced Renal Cell Carcinoma (RCC) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Advanced Renal Cell Carcinoma (RCC) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Advanced Renal Cell Carcinoma (RCC) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Advanced Renal Cell Carcinoma (RCC), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Advanced Renal Cell Carcinoma (RCC) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Advanced Renal Cell Carcinoma (RCC) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Advanced Renal Cell Carcinoma (RCC) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Advanced Renal Cell Carcinoma (RCC) market

Report Highlights

  • In the coming years, Advanced Renal Cell Carcinoma (RCC) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Renal Cell Carcinoma (RCC) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Advanced Renal Cell Carcinoma (RCC). Launch of emerging therapies will significantly impact the Advanced Renal Cell Carcinoma (RCC) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Advanced Renal Cell Carcinoma (RCC)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Advanced Renal Cell Carcinoma (RCC) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Advanced Renal Cell Carcinoma (RCC) Pipeline Analysis
  • Advanced Renal Cell Carcinoma (RCC) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Advanced Renal Cell Carcinoma (RCC) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Advanced Renal Cell Carcinoma (RCC) Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Advanced Renal Cell Carcinoma (RCC) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Advanced Renal Cell Carcinoma (RCC) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Advanced Renal Cell Carcinoma (RCC) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Advanced Renal Cell Carcinoma (RCC) market size during the forecast period (2017-2030)?
  • At what CAGR, the Advanced Renal Cell Carcinoma (RCC) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Advanced Renal Cell Carcinoma (RCC) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Advanced Renal Cell Carcinoma (RCC) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Advanced Renal Cell Carcinoma (RCC)?
  • What is the historical Advanced Renal Cell Carcinoma (RCC) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Advanced Renal Cell Carcinoma (RCC) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Advanced Renal Cell Carcinoma (RCC)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Advanced Renal Cell Carcinoma (RCC) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Advanced Renal Cell Carcinoma (RCC) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Advanced Renal Cell Carcinoma (RCC) in the USA, Europe, and Japan?
  • What are the Advanced Renal Cell Carcinoma (RCC) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Advanced Renal Cell Carcinoma (RCC)?
  • How many therapies are developed by each company for Advanced Renal Cell Carcinoma (RCC) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Advanced Renal Cell Carcinoma (RCC) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Advanced Renal Cell Carcinoma (RCC) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Advanced Renal Cell Carcinoma (RCC) and their status?
  • What are the key designations that have been granted for the emerging therapies for Advanced Renal Cell Carcinoma (RCC)?
  • What are the global historical and forecasted market of Advanced Renal Cell Carcinoma (RCC)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Advanced Renal Cell Carcinoma (RCC) market
  • To understand the future market competition in the Advanced Renal Cell Carcinoma (RCC) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Advanced Renal Cell Carcinoma (RCC) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Advanced Renal Cell Carcinoma (RCC) market
  • To understand the future market competition in the Advanced Renal Cell Carcinoma (RCC) market

Table of Contents

1. Key Insights

2. Executive Summary of Advanced Renal Cell Carcinoma (RCC)

3. Competitive Intelligence Analysis for Advanced Renal Cell Carcinoma (RCC)

4. Advanced Renal Cell Carcinoma (RCC): Market Overview at a Glance

  • 4.1. Advanced Renal Cell Carcinoma (RCC) Total Market Share (%) Distribution in 2017
  • 4.2. Advanced Renal Cell Carcinoma (RCC) Total Market Share (%) Distribution in 2030

5. Advanced Renal Cell Carcinoma (RCC): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Advanced Renal Cell Carcinoma (RCC) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Advanced Renal Cell Carcinoma (RCC) Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Advanced Renal Cell Carcinoma (RCC) Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Advanced Renal Cell Carcinoma (RCC) Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Advanced Renal Cell Carcinoma (RCC) Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Advanced Renal Cell Carcinoma (RCC) Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Advanced Renal Cell Carcinoma (RCC) Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Advanced Renal Cell Carcinoma (RCC) Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Advanced Renal Cell Carcinoma (RCC) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Advanced Renal Cell Carcinoma (RCC) Treatment and Management
  • 8.2. Advanced Renal Cell Carcinoma (RCC) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Advanced Renal Cell Carcinoma (RCC) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Advanced Renal Cell Carcinoma (RCC): Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Advanced Renal Cell Carcinoma (RCC) Market Size in 7MM
  • 13.3. Advanced Renal Cell Carcinoma (RCC) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Advanced Renal Cell Carcinoma (RCC) Total Market Size in the United States
    • 15.1.2. Advanced Renal Cell Carcinoma (RCC) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Advanced Renal Cell Carcinoma (RCC) Total Market Size in Germany
    • 15.3.2. Advanced Renal Cell Carcinoma (RCC) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Advanced Renal Cell Carcinoma (RCC) Total Market Size in France
    • 15.4.2. Advanced Renal Cell Carcinoma (RCC) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Advanced Renal Cell Carcinoma (RCC) Total Market Size in Italy
    • 15.5.2. Advanced Renal Cell Carcinoma (RCC) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Advanced Renal Cell Carcinoma (RCC) Total Market Size in Spain
    • 15.6.2. Advanced Renal Cell Carcinoma (RCC) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Advanced Renal Cell Carcinoma (RCC) Total Market Size in the United Kingdom
    • 15.7.2. Advanced Renal Cell Carcinoma (RCC) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Advanced Renal Cell Carcinoma (RCC) Total Market Size in Japan
    • 15.8.3. Advanced Renal Cell Carcinoma (RCC) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Advanced Renal Cell Carcinoma (RCC)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.